| Bioactivity | Bifikafusp alfa (L19-IL2) is an immunotherapy fusion protein consisting of human L19 antibodies fused to the human cytokine interleukin 2 (IL2).Bifikafusp alfa is specific to the EDB domain of fibronectin. Bifikafusp alfa has anticancer activity[1]. |
| In Vivo | Bifikafusp alfa (1.43 and 4.29 MIU/kg; i.p.; daily; for 10 days; 雌性 NMRI 裸鼠 MiaPaca-A2 异种移植) 对已建立的胰腺癌具有抗肿瘤活性[1]。 Animal Model: |
| Name | Bifikafusp alfa |
| CAS | 1957239-90-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wagner K, et, al. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin Cancer Res. 2008 Aug 1;14(15):4951-60. |